Do cystic fibrosis patients have hidden COVID protection?
NCT ID NCT05745948
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study followed 75 people with cystic fibrosis (CF) for two years to see how many developed COVID-19 antibodies from infection or vaccination. Researchers wanted to know if CF patients are naturally protected or just avoiding the virus. The study collected blood samples and health data to compare antibody levels and outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital Universitari Vall d'Hebron. Cystic Fibrosis Unit
Barcelona, Barcelona, 08035, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Can a new drug shield lungs from COVID-19's worst damage?
- Can paxlovid hold the line against severe COVID-19 outside the lab?